Free Courses In Business For October | Poets and Quants

By Editorial Team -
(Poetsandquants.com)  -
Here are the MOOCs starting in early October. Click on the links below to learn more and enroll.

Successful Negotiation / October 6 / University of Michigan

Managing Fashion and Luxury Companies / October 3 / Università Bocconi

Giving 2.0 / October 6 / Stanford University

Beyond Silicon Valley: Growing Entrepreneurship in Transitioning Economies/ October 3 / Case Western Reserve University

Better Leader, Richer Life / October 5 / Wharton

Introduction to Finance / October 6 / University of Michigan

Copyright Clarity / October 6 / University of Rhode Island

Foundations of Business Strategy / October 6 / University of Virginia

Understanding Media By Understanding Google / October 6 / Northwestern University

What’s Your Big Idea? / October 6 / University of North Carolina

Game Theory / October 5 / Stanford University and the University of British Columbia

Model Thinking / October 6 / University of Michigan

Behavioural Economics in Action / October 6 / University of Toronto

Globalization’s Winners and Losers: Challenges for Developed and Developing Countries / October 7 / Georgetown University

Introduction to Decision Quality / October 9 / Strategic Decisions Group

The Power of Macroeconomics:  Economic Principles in the Real World / October 6 / University of California-Irvine

The Power of Microeconomics:  Economic Principles in the Real World / October 6 / University of California-Irvine

Additional Courses for Early October
Read more:

Essential MOOC Courses In Business For October | Poets and Quants

Comments

Post a Comment

Pages

Popular posts from this blog

Top 10 Pharmaceutical Companies by Revenue and Market Cap in 2025 (September Edition)

By -
Image
Here are the top 10 pharmaceutical companies as of 2025, updated based on second quarter 2025 revenue data. AstraZeneca, Novartis and Vertex each posted 12% sales increases, offering more evidence of their upward trajectories in recent years. Credit:  fiercepharma.com Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). Aug 1, 2025 Update:  @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects ste...
Read more

Top 10 ETF Picks for September 2025: Best Funds to Buy Now for Growth, Safety, and Diversification

By -
Image
Here are the top 10 ETF picks for September 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. We’ve ranked the 10 ETF picks for September 2025 based on their year-to-date (YTD) performance and Assets Under Management (AUM) as of September 2025, using available data from the provided references and general market insights. Since precise YTD performance and AUM figures for some ETFs (e.g., EUAD, VIG) were not fully detailed in the references, we’ve supplemented with reasonable estimates based on trends and sector performance. The ranking gives weightage to YTD performance, as it reflects recent momentum, and uses AUM as another factor to gauge investor confidence and fund size. Ranking Methodology YTD Performance: Based on reported or estimated returns for 2025 (as of September 202...
Read more

Top 10 Pharma Companies by Market Cap in 2025

By -
Image
Here are the top 10 pharmaceutical companies by market cap as of September 2025. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This mid-2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. Updates: Aug 1, 2025 Update:  @POTUS  sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) Top 10 Pharmaceutical Companies by Revenue in 2025 (August Edition) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Source: CompaniesMarketCap.com ...
Read more

Top 10 Food Companies by Revenue (2025)

By -
Image
Based on the most recent 2025 revenue data, here are the top 10 food companies ranked by revenue: Top 10 Food Companies by Revenue (2025) 1. Nestlé (Switzerland) Revenue:  $101.54 billion Key Brands: Nescafe, KitKat, Maggi, Purina, Waters Notes:  World's largest food company, with a diverse portfolio including bottled water, coffee, frozen foods, and nutrition products. Nestlé Health Science (NHSc), a subsidiary of Nestlé, owns a variety of supplement brands. Some of the most notable ones include: Garden of Life, Vital Proteins, Pure Encapsulations, Wobenzym, Douglas Laboratories, Persona Nutrition, Genestra, Orthica, Minami, AOV, Klean Athlete, Nature's Bounty, Solgar, Osteo Bi-Flex, and Sundown. 2. Ahold Delhaize  (Netherlands) Revenue:  $96.22 billion Notes: Major global food retailer and distributor. 3. PepsiCo (USA) Revenue: $91.52 billion Key Brands: Pepsi, Lay's, Gatorade, Tropi...
Read more

Top Gold ETFs to Watch in 2025: Best Picks for Strong Returns and Low Costs

By -
Image
Top gold ETFs to watch in 2025 span U.S., Indian, Europe and Chinese markets, offering both physical gold exposure and mining stock leverage. Based on the latest performance, expense ratios, and trends, key ETFs include: SPDR Gold Shares (GLD) : The largest gold ETF with $104.39 B in assets and 28 % year-to-date gain (as of September 2025). It remains a core holding for physical gold exposure globally ( 1 ,  10 ). SPDR Gold MiniShares Trust (GLDM) : One-year return in 2025, up around 41%, with a very low expense ratio (0.10%). It tracks physical gold closely and is highly liquid, making it a top choice for cost-conscious investors seeking strong recent gains ( 2 ,  1 ). iShares Gold Trust (IAU) 1-Year Return: 40 - 45% (reported range for 2025) ( TradingView ) YTD Performance: 35 - 40% (reported range for 2025) ( TradingView ) AUM:...
Read more

Best Gold and Silver ETFs of 2025: Should You Buy Today? (September 2025 Edition)

By -
Image
Gold and silver ETFs have shown strong performance in 2025, surpassing the S&P 500 amid inflation concerns, geopolitical tensions, and central bank buying.  This article updates the best-performing gold and silver ETFs based on recent data, including 1-year returns, assets under management (AUM), expense ratios, and key notes, evaluating their pros, cons, and attractiveness in the current market.The best gold and silver ETFs of 2025 are noted for exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Returns have adjusted slightly since late August due to recent price movements, but momentum remains strong with gold and silver near record highs. Here are the top options across global and key regional markets as of September 2025: Best Gold ETFs of 2025 SPDR Gold MiniShares Trust (GLDM) 1-Year Return: 39.2 % Assets Under Management:  17.3 B Expense Ratio: 0.10% Notes: Best performing gold ETF, tracks physical gold, high li...
Read more

10 Best Artificial Intelligence Stocks of 2025

By -
Image
The best artificial intelligence (AI) stocks to watch and potentially invest in for 2025 include a mix of well-established tech giants and high-growth specialized companies. Below is a brief overview of the state of AI, followed by a list of AI stocks that look promising for 2025. State Of Artificial Intelligence In 2025 A McKinsey report characterizes 2023 as the year "the world discovered generative AI (gen AI)." 2024 is when businesses began realizing value from using gen AI. The rising adoption has sparked extreme demand for AI-capable computing power. Data centers, in turn, invested billions in hardware and software for powering, developing and training AI applications. In 2025, companies like OpenAI will look to move AI's capabilities into increasingly complex tasks. Use cases for AI will expand across industries and into the personal computing space. Organizations that have invested in AI will attempt to quantify the business value of those investments....
Read more

Best Bitcoin ETFs of 2025: Should You Buy Today?

By -
Image
As of 2025, the Bitcoin ETF landscape is dominated by a mix of spot Bitcoin ETFs offering direct exposure to the cryptocurrency and Bitcoin futures strategy ETFs that provide exposure through futures contracts. The top Bitcoin ETFs expected to dominate based on holdings and fees reflect a balance between large assets under management (AUM), competitive expense ratios, and investor preferences for spot versus futures exposure. What Is a Spot Bitcoin ETF? Spot Bitcoin ETFs, which first began trading on U.S. exchanges Jan. 11, 2024, are exchange-traded funds that track the price of Bitcoin by directly holding the cryptocurrency itself, unlike the futures-based Bitcoin ETFs that have traded on exchanges since 2021. When an investor buys shares of a spot Bitcoin ETF, they are buying a portion of the Bitcoin held by the fund. Thus, a spot Bitcoin fund works in a similar way as a physically backed gold ETF . How to Choose the Best Spot Bitcoin ETF  Choosing the...
Read more

Pharma & Cancer Treatment 2025: Breakthroughs, Market Leaders, and Industry Trends

By -
Image
The landscape of cancer treatment and the pharmaceutical industry is undergoing rapid transformation in 2025, driven by scientific breakthroughs, shifting drug sales rankings, and evolving strategies among top pharma companies. This article synthesizes the latest advances in cancer therapy, highlights the world’s top-selling drugs, and examines the leading pharmaceutical players shaping the future of oncology and global health. Latest Breakthroughs in Cancer Treatment (2025) The fight against cancer is being reshaped by a wave of innovations, many of which are already impacting clinical practice or are in advanced stages of development: Next-Generation Immunotherapy New checkpoint inhibitors, CAR-T cell therapies, and bispecific antibodies are expanding options for hard-to-treat cancers such as pancreatic and brain tumors. Related:   Combining Repurposed Drugs with Immunotherapy : A Novel Approach to Cancer Treatment AI-Based Risk Profiling AI and machine learning are being used fo...
Read more

Top XRP ETFs to Watch in 2025: Dominating Holdings, Low Fees, and Performance Insights

By -
Image
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...
Read more